Altimmune (ALT) Research & Development (2016 - 2025)
Historic Research & Development for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $15.0 million.
- Altimmune's Research & Development fell 2445.59% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year decrease of 1455.5%. This contributed to the annual value of $82.2 million for FY2024, which is 2496.54% up from last year.
- According to the latest figures from Q3 2025, Altimmune's Research & Development is $15.0 million, which was down 2445.59% from $17.2 million recorded in Q2 2025.
- Altimmune's Research & Development's 5-year high stood at $29.2 million during Q3 2021, with a 5-year trough of $11.9 million in Q1 2021.
- Moreover, its 5-year median value for Research & Development was $17.2 million (2023), whereas its average is $18.0 million.
- As far as peak fluctuations go, Altimmune's Research & Development surged by 12551.63% in 2021, and later tumbled by 3062.38% in 2022.
- Over the past 5 years, Altimmune's Research & Development (Quarter) stood at $20.2 million in 2021, then fell by 4.98% to $19.2 million in 2022, then fell by 11.84% to $16.9 million in 2023, then increased by 16.99% to $19.8 million in 2024, then fell by 24.37% to $15.0 million in 2025.
- Its Research & Development stands at $15.0 million for Q3 2025, versus $17.2 million for Q2 2025 and $15.8 million for Q1 2025.